SWA
CADL icon

Stratos Wealth Advisors’s Candel Therapeutics CADL Stock Holding History

Stratos Wealth Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
25,908
+2,908
+13% +$15.8K 0.01% 596
2025
Q4 		$130K Hold
23,000
– – 0.01% 637
2025
Q3 		$117K Hold
23,000
– – 0.01% 662
2025
Q2 		$116K Hold
23,000
– – 0.01% 651
2025
Q1 		$130K Buy
+23,000
New +$188K 0.01% 642

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stratos Wealth Advisors's CADL Position: Q1 2026 in Review

Stratos Wealth Advisors increased its Candel Therapeutics (CADL) stake by 13% in Q1 2026, buying an estimated $15.8K and bringing the position to 25,908 shares worth $127K. The position accounts for 0.01% of the portfolio, ranked #596.

Stratos Wealth Advisors first reported a position in CADL in Q1 2025 and has held it in 5 quarters since. The position peaked at $130K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Stratos Wealth Advisors held 25,908 shares of Candel Therapeutics worth $127K as of Q1 2026.
  • Stratos Wealth Advisors bought 2,908 Candel Therapeutics shares in Q1 2026, an estimated $15.8K.
  • Candel Therapeutics made up 0.01% of Stratos Wealth Advisors's portfolio in Q1 2026, its #596 holding.
  • Stratos Wealth Advisors first reported a position in Candel Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Stratos Wealth Advisors's Candel Therapeutics position peaked at $130K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.